miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells

[1]  B. Dörken,et al.  Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia , 2015, Annals of Hematology.

[2]  M. Caligiuri,et al.  Targeting Leukemia Stem Cells in vivo with AntagomiR-126 Nanoparticles in Acute Myeloid Leukemia , 2015, Leukemia.

[3]  Monika S. Kowalczyk,et al.  The MicroRNA-132 and MicroRNA-212 Cluster Regulates Hematopoietic Stem Cell Maintenance and Survival with Age by Buffering FOXO3 Expression. , 2015, Immunity.

[4]  C. Baldus,et al.  Outlook on PI3K/AKT/mTOR inhibition in acute leukemia , 2015, Molecular and Cellular Therapies.

[5]  Jian-Bing Fan,et al.  CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic Stem Cells , 2015, Cell stem cell.

[6]  Melinda J. Cromie,et al.  mTORC1 controls the adaptive transition of quiescent stem cells from G0 to GAlert , 2014, Nature.

[7]  A. Krešo,et al.  Evolution of the cancer stem cell model. , 2014, Cell stem cell.

[8]  G. Schuurhuis,et al.  Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. , 2014, Cancer Research.

[9]  N. Zeleznik-Le,et al.  Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. , 2014, The Journal of clinical investigation.

[10]  Ravinder Kandi,et al.  MicroRNAs as Haematopoiesis Regulators , 2013, Advances in hematology.

[11]  P. Pandolfi,et al.  The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. , 2013, Cell stem cell.

[12]  M. Caligiuri,et al.  A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia , 2013, Leukemia.

[13]  R. Larson,et al.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.

[14]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[15]  S. Kauppinen,et al.  Treatment of HCV infection by targeting microRNA. , 2013, The New England journal of medicine.

[16]  M. Minden,et al.  Influence of FLT3‐internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate‐risk karyotype acute myeloid leukemia , 2012, Cancer.

[17]  Gary D Bader,et al.  Attenuation of miR-126 Activity Expands HSC In Vivo without Exhaustion , 2012, Cell stem cell.

[18]  Margaret S. Ebert,et al.  Roles for MicroRNAs in Conferring Robustness to Biological Processes , 2012, Cell.

[19]  W. Fujibuchi,et al.  MiR-126 Acts as a Tumor Suppressor in Pancreatic Cancer Cells via the Regulation of ADAM9 , 2011, Molecular Cancer Research.

[20]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[21]  M. Greaves.  Cancer stem cells renew their impact , 2011, Nature Medicine.

[22]  B. Wittner,et al.  Asymmetric cancer cell division regulated by AKT , 2011, Proceedings of the National Academy of Sciences.

[23]  Debashis Sahoo,et al.  MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets , 2010, Proceedings of the National Academy of Sciences.

[24]  Alessandra Biffi,et al.  Identification of Hematopoietic Stem Cell–Specific miRNAs Enables Gene Therapy of Globoid Cell Leukodystrophy , 2010, Science Translational Medicine.

[25]  Aadel A. Chaudhuri,et al.  MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output , 2010, Proceedings of the National Academy of Sciences.

[26]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[27]  Todd R. Golub,et al.  MicroRNA miR-125a controls hematopoietic stem cell number , 2010, Proceedings of the National Academy of Sciences.

[28]  J. McCubrey,et al.  The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients , 2010, Oncotarget.

[29]  M. Birnbaum,et al.  AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species. , 2010, Blood.

[30]  M. Cleary,et al.  The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. , 2010, Cancer research.

[31]  I. Weissman,et al.  microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia , 2010, The Journal of experimental medicine.

[32]  A. Trumpp,et al.  Awakening dormant haematopoietic stem cells , 2010, Nature Reviews Immunology.

[33]  D. Gilliland,et al.  Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. , 2010, Blood.

[34]  R. Stallings,et al.  miR-126 Is Downregulated in Cystic Fibrosis Airway Epithelial Cells and Regulates TOM1 Expression , 2010, The Journal of Immunology.

[35]  T. Naoe,et al.  Cyclin C Regulates Human Hematopoietic Stem/Progenitor Cell Quiescence , 2009, Stem cells.

[36]  K. Anderson,et al.  Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia. , 2009, Blood.

[37]  Luigi Naldini,et al.  Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications , 2009, Nature Reviews Genetics.

[38]  B. Leber,et al.  A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over , 2009, Leukemia.

[39]  C. Bloomfield,et al.  MicroRNA expression in acute myeloid leukemia , 2009, Current hematologic malignancy reports.

[40]  P. Pandolfi,et al.  Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB , 2009, Nature Cell Biology.

[41]  I. Weissman,et al.  Hematopoietic stem cell quiescence is maintained by compound contributions of the retinoblastoma gene family. , 2008, Cell stem cell.

[42]  T. Golub,et al.  Distinct microRNA expression profiles in acute myeloid leukemia with common translocations , 2008, Proceedings of the National Academy of Sciences.

[43]  S. Morrison,et al.  The PI-3kinase pathway in hematopoietic stem cells and leukemia-initiating cells: a mechanistic difference between normal and cancer stem cells. , 2008, Blood cells, molecules & diseases.

[44]  George A Calin,et al.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. , 2008, Blood.

[45]  M. Minden,et al.  Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy , 2008, American journal of hematology.

[46]  S. Forman,et al.  Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. , 2007, Cancer research.

[47]  K. Inoki,et al.  Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. , 2006, Genes & development.

[48]  D. Bryder,et al.  Prolonged Cell Cycle Transit Is a Defining and Developmentally Conserved Hemopoietic Stem Cell Property1 , 2006, The Journal of Immunology.

[49]  Irving L. Weissman,et al.  Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates , 2005, The Journal of experimental medicine.

[50]  Shengjun Ren,et al.  Cyclin C/Cdk3 Promotes Rb-Dependent G0 Exit , 2004, Cell.

[51]  J. Harper,et al.  A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[52]  S. Hsu,et al.  Retinoic acid-mediated G1 arrest is associated with induction of p27(Kip1) and inhibition of cyclin-dependent kinase 3 in human lung squamous carcinoma CH27 cells. , 2000, Experimental cell research.

[53]  E. Lam,et al.  Inhibition of the Phosphoinositide 3-Kinase Pathway Induces a Senescence-like Arrest Mediated by p27Kip1 * , 2000, The Journal of Biological Chemistry.

[54]  G. Mills,et al.  The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells , 1999, Oncogene.

[55]  D. Hogge,et al.  Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-. , 1998, Blood.

[56]  T. Möröy,et al.  Investigation of the cell cycle regulation of cdk3-associated kinase activity and the role of cdk3 in proliferation and transformation , 1998, Oncogene.

[57]  S. van den Heuvel,et al.  Distinct roles for cyclin-dependent kinases in cell cycle control. , 1993, Science.